Agitation and aggression in people with Alzheimer's disease
The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
PURPOSE OF REVIEW: Agitation and aggression commonly arise in people with Alzheimer's disease (AD) and other dementias. They are distressing for the individual and often confer risk to them and to others, as well as raising significant clinical challenges. This review outlines the current evidence for pharmacological and nonpharmacological approaches to the treatment of agitation and aggression in these patients. RECENT FINDINGS: There is a growing body of literature supporting the use of nonpharmacological approaches as well as the treatment of pain as a first-line management strategy prior to psychopharmacotherapy. Antipsychotic medications are most commonly prescribed to address agitation and aggression. Evidence indicates this approach results in a modest but significant improvement in aggression in the short term (6-12 weeks) although the impact on other symptoms of agitation is limited. There is less positive evidence to support their use in the longer term, and prescriptions of more than 12 weeks and longer periods of prescription are associated with cumulative risk of severe adverse events, including death. Suggested pharmacological alternatives with the most promising preliminary evidence include memantine, carbamazepine, citalopram, and prazosin, but none of these agents have sufficient evidence in treating agitation and aggression to recommend use in routine clinical practice. SUMMARY: Currently, the best approach for managing these symptoms is within a framework of good practice that promotes prevention, monitoring and the use of nonpharmacological alternatives, with judicious short-term use of antipsychotics, when appropriate.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Schneider, L. S., Dagerman, K. S., & Insel, P. (2005) · JAMA · doi:10.1001/jama.294.15.1934 · Cited by 1,671 · cited 1×
“54) for all atypical antipsychotics [28], and this is supported by the DART-AD trial, which reported increased mortality in patients prescribed agents in the long term [29], and one further study [30], which demonstrated an even greater excess of mortality.”
ResultEffectiveness of Atypical Antipsychotic Drugs in Patients with Alzheimer's Disease
Schneider, L. S., Tariot, P. N., Dagerman, K. S., Davis, S. M., Hsiao, J. K., Ismail, M. S., Lebowitz, B. D., Lyketsos, C. G., Ryan, J. M., Stroup, T. S., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061240 · Cited by 1,206
Lyketsos, C. G., Steinberg, M., Tschanz, J. T., Norton, M. C., Steffens, D. C., & Breitner, J. C. S. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.5.708 · Cited by 1,144
Schneider, L. S., Dagerman, K., & Insel, P. S. (2006) · The American Journal of Geriatric Psychiatry · doi:10.1097/01.jgp.0000200589.01396.6d · Cited by 903
Donepezil and memantine for moderate-to-severe Alzheimer's disease
Howard, R., McShane, R., Lindesay, J., Ritchie, C., Baldwin, A., Barber, R., Burns, A., Dening, T., Findlay, D., Holmes, C., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1106668 · Cited by 782
Psychiatric symptoms and nursing home placement of patients with Alzheimer's disease
(1990) · American Journal of Psychiatry · doi:10.1176/ajp.147.8.1049 · Cited by 744
A Metaanalysis of Controlled Trials of Neuroleptic Treatment in Dementia
Schneider, L. S., Pollock, V. E., & Lyness, S. A. (1990) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1990.tb02407.x · Cited by 650 · cited 1×
“Eleven RCTs, mostly small in size and over 4–12 weeks, have evaluated the impact of treatment with typical antipsychotics on agitation and shown a significant but modest improvement compared with placebo (59 versus 41%) although it should be noted that trials report a very high placebo response [20].”
BackgroundQTc-interval abnormalities and psychotropic drug therapy in psychiatric patients
Reilly, J., Ayis, S., Ferrier, I., Jones, S., & Thomas, S. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02035-3 · Cited by 602
Husebo, B. S., Ballard, C., Sandvik, R., Nilsen, O. B., & Aarsland, D. (2011) · BMJ · doi:10.1136/bmj.d4065 · Cited by 571
Self-citationBallard, C., Hanney, M. L., Theodoulou, M., Douglas, S., McShane, R., Kossakowski, K., Gill, R., Juszczak, E., Yu, L.-M., & Jacoby, R. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70295-3 · Cited by 567
Self-citationChenoweth, L., King, M. T., Jeon, Y.-H., Brodaty, H., Stein-Parbury, J., Norman, R., Haas, M., & Luscombe, G. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70045-6 · Cited by 528
Efficacy and Tolerability of Carbamazepine for Agitation and Aggression in Dementia
Tariot, P. N., Erb, R., Podgorski, C. A., Cox, C., Patel, S., Jakimovich, L., & Irvine, C. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.1.54 · Cited by 422 · cited 1×
“Initial RCTs of anticonvulsants have indicated some promise, with two small parallel-group trials of carbamazepine over 6 weeks or less showing some potential benefit [51,52].”
BackgroundGitlin, L. N., Winter, L., Burke, J., Chernett, N., Dennis, M. P., & Hauck, W. W. (2008) · The American Journal of Geriatric Psychiatry · doi:10.1097/01.jgp.0000300629.35408.94 · Cited by 362
Treatment of agitation in AD: A randomized, placebo-controlled clinical trial
Teri, L., Logsdon, R. G., Peskind, E., Raskind, M., Weiner, M. F., Tractenberg, R. E., Foster, N. L., Schneider, L. S., Sano, M., Whitehouse, P., et al. (2000) · Neurology · doi:10.1212/wnl.55.9.1271 · Cited by 330 · cited 1×
“RCTs of sertraline [49] and trazadone [50] have been less promising.”
BackgroundPollock, B. G., Mulsant, B. H., Rosen, J., Sweet, R. A., Mazumdar, S., Bharucha, A., Marin, R., Jacob, N. J., Huber, K. A., Kastango, K. B., et al. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.3.460 · Cited by 327
Donepezil for the Treatment of Agitation in Alzheimer's Disease
Howard, R. J., Juszczak, E., Ballard, C. G., Bentham, P., Brown, R. G., Bullock, R., Burns, A. S., Holmes, C., Jacoby, R., Johnson, T., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066583 · Cited by 327 · cited 1×
“However, two RCTs evaluating donepezil and rivastigmine over 12 and 24 weeks, respectively, for the treatment of clinically significant agitation showed no treatment benefit [37,38], indicating that ChEIs do not appear to be useful in the management of acute agitation.”
BackgroundSelf-citationNeuroleptic drugs in dementia: benefits and harm
Ballard, C., & Howard, R. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1926 · Cited by 308 · cited 6×
“Despite this effect on aggression, however, there is no consistent evidence of benefit of risperidone for the treatment of nonaggressive symptoms of agitation such as restlessness and shouting [24,25].”
BackgroundSelf-citationPollock, B. G., Mulsant, B. H., Rosen, J., Mazumdar, S., Blakesley, R. E., Houck, P. R., & Huber, K. A. (2007) · The American Journal of Geriatric Psychiatry · doi:10.1097/jgp.0b013e3180cc1ff5 · Cited by 257 · cited 1×
“Unaut 0951-7367 2013 Wolters Kluwer Health | Lippincott Williams & Wilk the antipsychotic [48].”
BackgroundWilcock, G. K., Ballard, C. G., Cooper, J. A., & Loft, H. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0302 · Cited by 253
Self-citationGauthier, S., Loft, H., & Cummings, J. (2008) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.1949 · Cited by 220
Fox, C., Crugel, M., Maidment, I., Auestad, B. H., Coulton, S., Treloar, A., Ballard, C., Boustani, M., Katona, C., & Livingston, G. (2012) · PLoS ONE · doi:10.1371/journal.pone.0035185 · Cited by 173
Self-citationOlin, J. T., Fox, L. S., Pawluczyk, S., Taggart, N. A., & Schneider, L. S. (2001) · The American Journal of Geriatric Psychiatry · doi:10.1097/00019442-200111000-00008 · Cited by 163 · cited 1×
“Initial RCTs of anticonvulsants have indicated some promise, with two small parallel-group trials of carbamazepine over 6 weeks or less showing some potential benefit [51,52].”
BackgroundKonovalov, S., Muralee, S., & Tampi, R. R. (2007) · International Psychogeriatrics · doi:10.1017/s1041610207006540 · Cited by 126
The utility of pain assessment for analgesic use in persons with dementia
Cohen-Mansfield, J., & Lipson, S. (2008) · Pain · doi:10.1016/j.pain.2007.03.023 · Cited by 62
Neuroleptic Drugs in the Management of Behavioral Symptoms of Alzheimer’s Disease
Tune, L. E., Steele, C., & Cooper, T. (1991) · Psychiatric Clinics of North America · doi:10.1016/s0193-953x(18)30312-5 · Cited by 47 · cited 2×
“Anticholinergic effects of many atypical antipsychotics are also thought to increase the risk of delirium [22,24].”
BackgroundTrinh, N.-H., Hoblyn, J., Mohanty, S., & Yaffe, K. (2003) · JAMA · doi:10.1001/jama.289.2.210 · Cited by 37
Cited by
Ballard, C., Corbett, A., Orrell, M., Williams, G., Moniz-Cook, E., Romeo, R., Woods, B., Garrod, L., Testad, I., Woodward-Carlton, B., et al. (2018) · PLOS Medicine · doi:10.1371/journal.pmed.1002500 · Cited by 263
Self-citationKales, H. C., Lyketsos, C. G., Miller, E. M., & Ballard, C. (2019) · International Psychogeriatrics · doi:10.1017/s1041610218000534 · Cited by 220
“First published online 2 August 2018. psychological symptoms of dementia (BPSD), such as agitation, aggression and psychosis, during the course of their dementia (Ballard and Corbett, 2013).”
BackgroundSelf-citationPless, A., Ware, D., Saggu, S., Rehman, H., Morgan, J., & Wang, Q. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1263771 · Cited by 131
Beta-amyloid short- and long-term synaptic entanglement
Lanni, C., Fagiani, F., Racchi, M., Preda, S., Pascale, A., Grilli, M., Allegri, N., & Govoni, S. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2018.11.018 · Cited by 29
Brexpiprazole for the Treatment of Agitation and Aggression in Alzheimer Disease
Ballard, C. (2023) · JAMA Neurology · doi:10.1001/jamaneurol.2023.3967 · Cited by 14
Self-citation
Metadata
- Authors
- Ballard, C., & Corbett, A.
- Venue
- Current Opinion in Psychiatry
- Published
- 2013-05
- Volume
- 26
- Issue
- 3
- Pages
- 252-259
- ISSN
- 0951-7367 (ISSN-L)
- OpenAlex
- W2060787282
- Cited by
- 128
- References
- 26
- FWCI
- 7.23
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.